Search

Your search keyword '"Saglam, Burcin"' showing total 9 results
Start Over Author "Saglam, Burcin"
9 results on '"Saglam, Burcin"'

1. Competences of internal medicine specialists for the management of patients with multimorbidity. EFIM multimorbidity working group position paper

Author

Angermann, Christiane, Battegay, Edouard, Bernabeu-Wittel, Máximo, Bryant, Catherine, Elis, Avishay, Ertl, Georg, Gómez-Huelgas, Ricardo, Grine, Sabrina, Holecki, Michal, Kürrle, Annette, Lidove, Olivier, Para, Ombretta, Saglam, Burcin, Santos, Lelita, Tuttolomondo, Antonino, Václavik, Jan, van Munster, Barbara, Voicehovska, Julija, Bernabeu-Wittel, M, Para, O, Voicehovska, J, Gómez-Huelgas, R, Václavík, J, Battegay, E, Holecki, M, and van Munster, B.C.

Published
2023
Full Text
View/download PDF

2. Competences of internal medicine specialists for the management of patients with multimorbidity. EFIM multimorbidity working group position paper

Author

Bernabeu-Wittel, M, primary, Para, O, additional, Voicehovska, J, additional, Gómez-Huelgas, R, additional, Václavík, J, additional, Battegay, E, additional, Holecki, M, additional, van Munster, B.C., additional, Angermann, Christiane, additional, Battegay, Edouard, additional, Bernabeu-Wittel, Máximo, additional, Bryant, Catherine, additional, Elis, Avishay, additional, Ertl, Georg, additional, Gómez-Huelgas, Ricardo, additional, Grine, Sabrina, additional, Holecki, Michal, additional, Kürrle, Annette, additional, Lidove, Olivier, additional, Para, Ombretta, additional, Saglam, Burcin, additional, Santos, Lelita, additional, Tuttolomondo, Antonino, additional, Václavik, Jan, additional, van Munster, Barbara, additional, and Voicehovska, Julija, additional

Published
2023
Full Text
View/download PDF

3. Multiomics Analysis Reveals the Impact of Microbiota on Host Metabolism in Hepatic Steatosis

Author

Zeybel, Mujdat, primary, Arif, Muhammad, additional, Li, Xiangyu, additional, Altay, Ozlem, additional, Yang, Hong, additional, Shi, Mengnan, additional, Akyildiz, Murat, additional, Saglam, Burcin, additional, Gonenli, Mehmet Gokhan, additional, Yigit, Buket, additional, Ulukan, Burge, additional, Ural, Dilek, additional, Shoaie, Saeed, additional, Turkez, Hasan, additional, Nielsen, Jens, additional, Zhang, Cheng, additional, Uhlén, Mathias, additional, Borén, Jan, additional, and Mardinoglu, Adil, additional

Published
2022
Full Text
View/download PDF

4. Combined metabolic activators therapy ameliorates liver fat in nonalcoholic fatty liver disease patients

Author

Zeybel, Mujdat, primary, Altay, Ozlem, additional, Arif, Muhammad, additional, Li, Xiangyu, additional, Yang, Hong, additional, Fredolini, Claudia, additional, Akyildiz, Murat, additional, Saglam, Burcin, additional, Gonenli, Mehmet Gokhan, additional, Ural, Dilek, additional, Kim, Woonghee, additional, Schwenk, Jochen M, additional, Zhang, Cheng, additional, Shoaie, Saeed, additional, Nielsen, Jens, additional, Uhlén, Mathias, additional, Borén, Jan, additional, and Mardinoglu, Adil, additional

Published
2021
Full Text
View/download PDF

5. Multi-omics analysis reveals the impact of microbiota on host metabolism in hepatic steatosis

Author

Zeybel, Mujdat, primary, Arif, Muhammad, additional, Li, Xiangyu, additional, Altay, Ozlem, additional, Shi, Mengnan, additional, Akyildiz, Murat, additional, Saglam, Burcin, additional, Gonenli, Mehmet Gokhan, additional, Yigit, Buket, additional, Ulukan, Burge, additional, Ural, Dilek, additional, Shoaie, Saeed, additional, Turkez, Hasan, additional, Nielsen, Jens, additional, Zhang, Cheng, additional, Uhlén, Mathias, additional, Borén, Jan, additional, and Mardinoglu, Adil, additional

Published
2021
Full Text
View/download PDF

6. Combined Metabolic Activators Reduces Liver Fat in Nonalcoholic Fatty Liver Disease Patients

Author

Zeybel, Mujdat, primary, Altay, Ozlem, additional, Arif, Muhammad, additional, Li, Xiangyu, additional, Yang, Hong, additional, Fredolini, Claudia, additional, Akyildiz, Murat, additional, Saglam, Burcin, additional, Gonenli, Mehmet Gokhan, additional, Ural, Dilek, additional, Kim, Woonghee, additional, Schwenk, Jochen M., additional, Zhang, Cheng, additional, Shoaie, Saeed, additional, Nielsen, Jens, additional, Uhlén, Mathias, additional, Borén, Jan, additional, and Mardinoglu, Adil, additional

Published
2021
Full Text
View/download PDF

7. Combined Metabolic Cofactor Supplementation Reduces Liver Fat in Nonalcoholic Fatty Liver Disease

Author

Zeybel, Mujdat, primary, Altay, Ozlem, additional, Arif, Muhammad, additional, Li, Xiangyu, additional, Yang, Hong, additional, Fredolini, Claudia, additional, Akyildiz, Murat, additional, Saglam, Burcin, additional, Gonenli, Mehmet Gokhan, additional, Ural, Dilek, additional, Kim, Woonghee, additional, Schwenk, Jochen M., additional, Zhang, Cheng, additional, Shoaie, Saeed, additional, Nielsen, Jens, additional, Uhlen, Mathias, additional, Boren, Jan, additional, and Mardinoglu, Adil, additional

Published
2021
Full Text
View/download PDF

8. Bortezomib induced pulmonary toxicity: a case report and review of the literature

Author

Saglam, Burcin, Kalyon, Hakan, Ozbalak, Murat, Ornek, Serdar, Şiran Keske, Tabak, Levent, Cakar, Nahit, Zeren, Ha Ndan, Aytekin, Saide, Bolukbasi, Yasemin, and Ferhanogu, Burhan

Subjects
hemic and lymphatic diseases, Bortezomib, lung injury, pulmonary toxicity, proteasome inhibitor, multiple myeloma, Case Report
Abstract

Bortezomib is widely used in the treatment of Multiple Myeloma. While the most common side effects are neurological and gastrointestinal related complications, severe pulmonary problems are rarely described. The present case is a 72-year old male with multiple myeloma, who received Lenalidomide, Bortezomib, and Dexamethasone (RVD) combination regimen. He underwent 30 Gy palliative radiotherapy to the thoracic 5-9 and lumbar L1-3 vertebra due to pain and fracture risk. During the third cycle, he was admitted to hospital with dyspnea and dizziness. The thoracic CT revealed bilateral pleural effusions, a diffuse reticular pattern on the parenchyma, and ground-glass opacities that were compatible with drug-induced lung injury. The microbiological and molecular analysis excluded infectious disease, and lung biopsy confirmed the diagnosis of Bortezomib Lung Injury. The time from the first dose of Bortezomib to the lung injury was 57 days, and it was five days from the last dose of Bortezomib. His symptoms were refractory to IV steroids and supportive care. Our patient was lost despite steroids and intensive care support. Even Bortezomib induced lung injury is a rare adverse effect, based on high mortality rate, we would like to emphasize the clinical importance of this clinical scenario in light of the published literature and our presented case.

9. Bortezomib induced pulmonary toxicity: a case report and review of the literature.

Author

Saglam B, Kalyon H, Ozbalak M, Ornek S, Keske S, Tabak L, Cakar N, Zeren H, Aytekin S, Bolukbasi Y, and Ferhanoglu B

Abstract

Bortezomib is widely used in the treatment of Multiple Myeloma. While the most common side effects are neurological and gastrointestinal related complications, severe pulmonary problems are rarely described. The present case is a 72-year old male with multiple myeloma, who received Lenalidomide, Bortezomib, and Dexamethasone (RVD) combination regimen. He underwent 30 Gy palliative radiotherapy to the thoracic 5-9 and lumbar L1-3 vertebra due to pain and fracture risk. During the third cycle, he was admitted to hospital with dyspnea and dizziness. The thoracic CT revealed bilateral pleural effusions, a diffuse reticular pattern on the parenchyma, and ground-glass opacities that were compatible with drug-induced lung injury. The microbiological and molecular analysis excluded infectious disease, and lung biopsy confirmed the diagnosis of Bortezomib Lung Injury. The time from the first dose of Bortezomib to the lung injury was 57 days, and it was five days from the last dose of Bortezomib. His symptoms were refractory to IV steroids and supportive care. Our patient was lost despite steroids and intensive care support. Even Bortezomib induced lung injury is a rare adverse effect, based on high mortality rate, we would like to emphasize the clinical importance of this clinical scenario in light of the published literature and our presented case., Competing Interests: None., (AJBR Copyright © 2020.)

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results